Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
This research evaluates atezolizumab as an additional treatment for patients with malignant pleural mesothelioma who have undergone surgical removal of the tumor and show no visible remaining disease. This phase III trial compares atezolizumab to a placebo to assess how well it works in preventing disease recurrence. Patients are grouped based on tumor type and cancer stage to better understand treatment effects. Participants receive either atezolizumab at 1200 mg or a matching placebo every 21 days for up to 12 months, or until the disease returns, side effects become unacceptable, or the patient or doctor decide to stop treatment. The study uses a centralized system to randomly assign patients to one of these groups, ensuring a balanced comparison. Tumor samples are analyzed to study biological markers and gene expression. During the trial, patients undergo CT scans before starting treatment and then every 12 weeks for two years or until the disease progresses. Quality of life questionnaires are completed at the start and every 12 weeks. Researchers monitor safety, disease-free survival, and overall survival for up to a year. The study lasts several years, with follow-up assessments to understand treatment impact and patient well-being.
Actively Recruiting
Researchers are evaluating the use of BIOTRONIK dual-chamber pacemakers that combine left bundle branch area pacing LBBAP with Closed Loop Stimulation CLS in patients who have sinus node dysfunction SND and atrioventricular AV conduction disorders. This observational study aims to understand how this combined pacing method works in everyday clinical practice and whether it can help reduce atrial fibrillation detected by the device over 24 months. The goal is to gather real-world evidence to optimize pacemaker programming and improve patient outcomes. Participants receive permanent dual-chamber pacemakers with a ventricular lead placed in the left bundle branch area, activating the CLS rate-responsive algorithm. The study focuses on patients implanted with these devices who have no prior history of atrial fibrillation. The study follows about 150 patients for 24 months after implantation, collecting data on device-detected atrial fibrillation episodes, heart rate patterns, and pacing behavior. This is a prospective observational submodule of the BIOSTREAM.CSP registry without a control group. During the study, researchers monitor device-recorded atrial fibrillation incidence and burden from CLS activation up to 24 months. They also analyze heart rate histograms at one and two years after implantation. Patients are enrolled in the BIOSTREAM.CSP registry and are followed through routine clinical care with data collected on pacing rates and arrhythmia episodes. The study aims to provide insights into the clinical performance of CLS combined with LBBAP to inform decisions on pacemaker programming and reduce atrial arrhythmias.
Actively Recruiting
The registry is designed to evaluate the outcomes, performance, and safety of BIOTRONIK devices used in conduction system pacing CSP through long-term data collected in real-world clinical settings. It includes patients who receive these devices as part of routine care to better understand their use and effects over time. The study is observational and collects data from unselected patients without intervention by the researchers. Participants receive BIOTRONIK devices for conduction system pacing, including the implantation of the Solia CSP S pacing lead for left bundle branch area pacing LBBAP. The study includes patients who are newly implanted, recently implanted but not yet discharged, or transitioning from a related study. The registry tracks device performance and safety over an average of 4 years through annual assessments. During the study, participants will undergo evaluations including the rate of device-related serious adverse events, success of acute implantation, capture type at implantation, long-term maintenance of pacing, and electrical parameters such as pacing threshold, sensing amplitude, and impedance. Participants will use the BIOTRONIK Home Monitoring system with the CardioMessenger device to support follow-up, which requires their willingness and ability to comply with study visits and monitoring over time.
Actively Recruiting
Healthy Volunteer
This research investigates the coping strategies and attachment dynamics in children with cancer and their parents. It focuses on how parents ways of managing stress influence their childrens coping during cancer treatment. The study aims to better understand emotional resources and psychological factors such as resilience, social support, and emotional states of caregivers in pediatric oncohematology. Participants include pediatric patients aged 8 to 17 receiving treatment at Pediatric Oncohematology departments and their parents. The study involves a single administration of psychological tests to both parents and patients shortly after enrollment. This cross-sectional observational study assesses coping strategies and attachment relationships without intervention or treatment assignment. During the study, participants complete psychological assessments including the Child-Parent Relationship Scale and Coping Orientations to Problem Experienced, all conducted once soon after joining. Researchers measure emotional and attachment factors influencing coping. The study is sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia and participation spans a one-time assessment within the treatment period.
Actively Recruiting
Researchers are investigating how adding a therapeutic dose of oxygen during exercise affects people with chronic respiratory failure or exertional hypoxemia due to chronic obstructive pulmonary disease COPD or interstitial lung disease. This multicenter crossover trial aims to evaluate exercise performance, gas exchange, heart rate, symptom perception, and ease of performing exercise in patients hospitalized in pulmonary rehabilitation centers. The study will compare walking ability during two conditions using the 6-minute walk test to understand the benefits of different oxygen levels during exertion. Participants will perform two 6-minute walk tests in random order within 24 hours. One test uses their usual oxygen flow prescribed at rest or room air for those with exertional hypoxemia, while the other uses double the prescribed oxygen flow or 2 liters per minute for patients with exertional hypoxemia. Oxygen is delivered through nasal cannulas with a stroller carrying the oxygen supply. Tests are separated by at least 3 hours. The study groups include patients with COPD with exertional hypoxemia, COPD with chronic respiratory failure on long-term oxygen therapy, and interstitial lung disease with chronic respiratory failure on long-term oxygen therapy. Participants will be assessed for walking distance, oxygen saturation, heart rate, blood pressure, and symptoms such as breathlessness and fatigue before, during, and after the tests. A questionnaire will capture how easy participants found the test. Researchers will analyze the difference in walking distance between conditions as the primary outcome. The study will also examine how clinical and anthropometric factors influence responses to oxygen therapy. The total planned enrollment is 114 patients, and the trial will provide insights for better oxygen therapy prescriptions during exercise.
Actively Recruiting
Researchers are conducting the RICMAF Study, an observational, multicenter, non-drug study in Italy focused on Anderson-Fabry Disease AFD, a rare genetic disorder that affects multiple organs, especially the heart. The study aims to better understand AFDs clinical course, its cardiac complications, and the relationship between genetic mutations and disease progression. This research seeks to improve patient care by identifying early markers of heart involvement and predicting cardiovascular problems. The study collects data from patients diagnosed with AFD according to international guidelines, starting from January 1, 1981, through December 31, 2031. It includes both retrospective and prospective phases, gathering comprehensive clinical, genetic, laboratory, and imaging information through a national patient registry. Patients undergo regular assessments as part of their standard care, including cardiology evaluations, ECG, echocardiography, and cardiac MRI when appropriate. Participants contribute data during routine clinical visits without additional study-specific procedures. The research team collects information from medical records and follow-up visits, including family history, symptoms, genetic tests, and heart monitoring results. The primary outcome is to define the natural history of Fabry disease over an average follow-up of five years, while secondary outcomes focus on cardiac risk stratification, genotype correlations, and early diagnostic biomarkers. The study duration extends up to 10 years, with ongoing data analysis and publication of findings.
Actively Recruiting
This research investigates two surgical techniques for treating multiple gingival recessions, which are areas where the gum has receded from teeth. The trial compares the split-thickness non-advanced tunnel method with the full-thickness coronally-advanced tunnel MCAT approach to evaluate which provides better root coverage. The study is a randomized, outcome-assessor blinded clinical trial conducted at multiple centers, focusing on patients with specific types of gum recession who need root coverage treatment. Participants will be randomly assigned to one of two groups one receiving the split-thickness non-advanced tunnel procedure, and the other undergoing the full-thickness coronally-advanced tunnel MCAT surgery. Each technique follows established methods from previous studies. The main treatment period lasts six months, with an option to extend follow-up to three or five years if funding permits. During the study, participants will undergo assessments including measurements of root coverage at three and six months after surgery. Various clinical and digital evaluations will monitor gum tissue changes, tooth attachment, pocket depth, dental sensitivity, and aesthetic outcomes. The primary outcome is the average root coverage achieved at six months, measured by a blinded assessor. Participants will attend follow-up visits and have their oral health carefully monitored throughout the study period.
Actively Recruiting
Researchers are studying patients with poor grade aneurysmal subarachnoid hemorrhage to understand outcomes, predictors, and treatment effects. The study focuses on three key areas early brain injury phase in the emergency department, delayed brain injury phase in the neurocritical care unit, and treatment strategies. Additional research addresses delayed cerebral ischemia and long-term follow-up, as some patients may improve significantly after 6 to 12 months. This observational study includes patients with poor grade subarachnoid hemorrhage managed according to the latest international and national guidelines. Both prospective and retrospective patients are included, and treatment follows established protocols. The study does not involve experimental treatments but observes standard care practices. Participants will have their clinical outcomes measured at 6 and 12 months after hemorrhage, with additional long-term follow-up up to 60 months. Researchers will also track delayed cerebral ischemia, rebleeding, treatment complications, and surgical interventions within specified timeframes. Imaging analyses will assess bleeding volumes and ischemic changes. The study aims to provide detailed outcome data and predictors over both short and long terms.
Actively Recruiting
Researchers are evaluating the long-term reliability and performance of cardiac rhythm products marketed by Medtronic. This observational study focuses on devices such as leads, implantable pulse generators, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices used for conditions like arrhythmia, bradycardia, heart failure, and sinus tachycardia. The study aims to analyze product survival probabilities and monitor lead-related complications over time. Participants include individuals who have received or will receive Medtronic market-released cardiac devices for pacing, sensing, or defibrillation. The study includes products implanted as part of routine care or participants from prior qualifying studies. Data is collected from the time of implantation and continues until the device is removed from service, the patient exits the study, or passes away. Enrollment criteria also require consent for access to health information. During the study, participants device performance is monitored through follow-up data collection. Researchers assess complications related to the implanted leads and track device status over long periods, potentially spanning several years. The study does not involve additional treatments but relies on routine clinical follow-up and health information review. The total duration extends up to December 2040, allowing comprehensive long-term evaluation of device performance.
Actively Recruiting
This observational registry study is designed to continuously evaluate and periodically report on the safety and effectiveness of Medtronic market-released medical products. It aims to support patients, hospitals, clinicians, regulatory bodies, payers, and the medical industry by streamlining clinical surveillance and enhancing performance assessment with minimal burden. Participants include patients who have received or are intended to receive an eligible Medtronic product. The registry collects data related to various conditions such as cardiac rhythm disorders, neurological disorders, cardiovascular disorders, and several others, with ongoing monitoring every 6 to 12 months depending on the therapy. During the study, participants provide consent and data is collected during routine care and follow-up visits. The research team reviews safety and effectiveness outcomes regularly to understand product performance over time. The study is planned to continue until January 2040, allowing for long-term monitoring and reporting.
1-10 of 11
1